HER2-Positive Bladder Cancer Treatment Before Surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two new drugs (trastuzumab rezetecan and adebrelimab) given before surgery to remove bladder cancer. The drugs target HER2, a protein found on some bladder cancer cells, and may help shrink tumors and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with good overall health (able to do light activity)
- Bladder cancer confirmed by biopsy that has spread into the muscle layer but not to distant organs
- Cancer cells must have HER2 protein (special marker) visible under microscope
- Never received chemotherapy before this trial
- No active autoimmune diseases (like rheumatoid arthritis) or uncontrolled heart problems
- Blood counts, kidney, and liver function tests must be close to normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (trastuzumab rezetecan and camrelizumab) given before and after surgery to remove the bladder in patients with HER2-positive muscle-invasive bladder cancer. The goal is to improve survival and reduce cancer recurrence in this aggressive type of bladder cancer.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This trial tests a new antibody-drug (RC48-ADC) together with an immunotherapy medicine (triplizumab) given before bladder surgery. It’s for people with HER2-positive muscle-invasive bladder cancer who may benefit from shrinking the tumor before radical cystectomy.
This trial tests a new targeted drug (disitamab vedotin) combined with immunotherapy against the standard chemotherapy-immunotherapy combination for muscle-invasive bladder cancer that expresses HER2 protein. The goal is to see if the new approach works better and is safer for patients before bladder removal surgery.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
Hear when a new Muscle-Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.